美股A股
StockGist
Back
8-K2026-04-13· deepseek-chat

ALLO · Allogene Therapeutics, Inc.

0001193125-26-151999

SEC filing

Summary

Allogene Therapeutics announced interim futility analysis from its pivotal Phase 2 ALPHA3 trial of cema-cel in first-line consolidation for large B-cell lymphoma, showing 58.3% of patients in the treatment arm achieved MRD negativity compared to 16.7% in the observation arm.

Key takeaways